Cargando…

Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia

Detalles Bibliográficos
Autores principales:	Gokhale, Yojana, Mehta, Rakshita, Karnik, Nitin, Kulkarni, Uday, Gokhale, Sushant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365119/ https://www.ncbi.nlm.nih.gov/pubmed/32691021 http://dx.doi.org/10.1016/j.eclinm.2020.100467

Ejemplares similares

Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India
por: Gokhale, Yojana, et al.
Publicado: (2021)

Dapsone-induced neutropenia with invasive pulmonary aspergillosis
por: Sabnis, Girish R., et al.
Publicado: (2012)

Auditing the efficacy of prophylactic measures against Covid-19 amongst Healthcare workers in India
por: Pillai, Ashwin, et al.
Publicado: (2021)

Nodular scleritis as a presenting feature of Takayasu's arteritis
por: Shukla, Eesha, et al.
Publicado: (2016)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

High-flow nasal oxygen in severe COVID-19 pneumonia and tocilizumab
por: Mandal, M., et al.
Publicado: (2022)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients
por: Piconi, Stefania, et al.
Publicado: (2023)

Authors’ reply
por: Gokhale, Nikhil S
Publicado: (2016)

Theoretical assessment of persistence and adaptation in weeds with complex life cycles
por: Lauenroth, Dana, et al.
Publicado: (2023)

Efficacy of tocilizumab treatment in severely ill COVID-19 patients
por: Zhao, Jie, et al.
Publicado: (2020)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab
por: Gentile, Giorgio, et al.
Publicado: (2021)

Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia
por: Shinomiya, Shohei, et al.
Publicado: (2021)

Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
por: Alex, Ruth, et al.
Publicado: (2022)

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Acute-Onset Psychosis Following Prolonged Hospitalization for COVID-19 Pneumonia
por: Zhang, Jeff F., et al.
Publicado: (2022)

How sequence populations persist inside bacterial genomes
por: Park, Hye Jin, et al.
Publicado: (2021)

Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab
por: Comel, Andrea Claudio, et al.
Publicado: (2020)

Severe necrotising inflammatory skin reaction to topical 5-fluorouracil
por: Gokhale, Nikhil S
Publicado: (2019)

Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis
por: Roumier, Mathilde, et al.
Publicado: (2020)

Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study
por: Janapala, Rajesh Naidu, et al.
Publicado: (2021)

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes
por: Al-Baadani, Abeer, et al.
Publicado: (2021)

Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab
por: Adre, Lorenzo Abednego B, et al.
Publicado: (2023)

Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia
por: Górgolas Hernández-Mora, Miguel, et al.
Publicado: (2021)

A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort
por: Ruiz-Antorán, Belén, et al.
Publicado: (2021)

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
por: Salama, Carlos, et al.
Publicado: (2020)

Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm
por: Gokhale, Nikhil S
Publicado: (2016)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Smartphone-assisted retinal evaluation in COVID-19 admitted patients
por: Sarkar, Sandip, et al.
Publicado: (2021)

PREVOTELLA BIVIA BACTEREMIA POST TOCILIZUMAB IN A PATIENT WITH SEVERE COVID-19 PNEUMONIA
por: AIYANYOR, ALFRED, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c99f6on4s84isuf50qcei3umj3